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Abstract
Objective—To validate clinical indices of lupus nephritis (LN) activity and damage when used 
in children against the criterion standard of kidney biopsy findings.
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Methods—In 83 children requiring kidney biopsy the SLE Disease Activity Index Renal Domain 
(SLEDAI-R); British Isles Lupus Assessment Group index Renal Domain (BILAG-R), Systemic 
Lupus International Collaborating Clinics Renal Activity (SLICC-RAS) and Damage Index Renal 
Domain (SDI-R) were measured. Fixed effect and logistic models were done to predict 
International Society of Nephrology/Renal Pathology Society (ISN/RPS) class; low/moderate vs. 
high LN-activity [NIH Activity Index (NIH-AI) score: ≤ 10 vs. > 10; Tubulointerstitial Activity 
Index (TIAI) score: ≤ 5 vs. > 5) or the absence vs. presence of LN chronicity [NIH Chronicity 
Index (NIH-CI) score: 0 vs. ≥ 1].
Results—There were 10, 50 and 23 patients with class I/II, III/IV and V, respectively. Scores of 
the clinical indices did not differentiate among patients by ISN/RPS class. The SLEDAI-R and 
SLICC-RAS but not the BILAG-R differed with LN-activity status defined by NIH-AI scores, 
while only the SLEDAI-R scores differed between LN-activity status based on TIAI scores. The 
sensitivity and specificity of the SDI-R to capture LN chronicity was 23.5% and 91.7%, 
respectively. Despite designed to measure LN-activity, SLICC-RAS and SLEDAI-R scores 
significantly differed with LN chronicity status.
Conclusion—Current clinical indices of LN fail to discriminate ISN/RPS Class in children. 
Despite its shortcomings, the SLEDAI-R appears to best for measuring LN activity in a clinical 
setting. The SDI-R is a poor correlate of LN chronicity.
Key Terms
Lupus nephritis; SLE; Children; Biomarkers
INTRODUCTION
Kidney biopsies are performed in systemic lupus erythematosus (SLE) to establish the 
diagnosis of lupus nephritis (LN) (1). Correlates of active inflammatory and chronic 
degenerative changes as seen on kidney biopsy assist with clinical decision making on the 
types and intensity of treatments in an attempt to protect long-term kidney function. 
Conversely, kidney biopsies are not used for routine monitoring of LN (2, 3), given cost and 
invasiveness. Instead laboratory testing, i.e. urinalysis and sediment, complement levels, 
anti-double stranded DNA antibody levels, timed proteinuria, protein: creatinine ratio (P/C 
ratio), blood pressure and glomerular filtration rate are performed for monitoring the course 
of LN in the clinical setting. Several clinical indices have been developed for adults with 
LN. These include the renal domain scores of the Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI-R) and of the British Isles Lupus Assessment Group index 
(BILAG-R) (4) as well as the Systemic Lupus International Collaborating Clinics Renal 
Activity Score (SLICC-RAS) (5). Further, the SLICC Damage Index Renal Domain Score 
(SDI-R) is used to monitor and quantify kidney damage with LN.
Despite widespread use, these indices have not been well validated against the criterion 
standard, i.e. histological correlates of LN activity and chronicity as well as seen on kidney 
biopsy in pediatric populations with LN (6–9). This seems important given known 
differences in renal parameters between children and adults.
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The objective of this study was to validate clinical indices of LN activity and damage when 
used in children against the criterion standard, i.e. findings on kidney biopsy.
MATERIALS & METHODS
Patients
Study participants were children who fulfilled the 1997 American College of Rheumatology 
(ACR) classification criteria for systemic lupus erythematosus (SLE) (10) prior to 18 years 
of age and required a kidney biopsy for diagnosis or follow-up of LN. For each patient, 
clinical and standard of care laboratory information including the findings on kidney biopsy 
were collected at the time of kidney biopsy. LN clinical indices were compared against 
criterion standards for LN activity and LN damage. The institutional review boards of the 13 
participating pediatric rheumatology centers approved this cross-sectional study. All parents 
gave informed consent and, as appropriate, participants gave assent prior to the study 
procedures.
Clinical indices
The SLEDAI-R score (range 0–16; 0 = inactive LN) represents the sum of the renal items of 
the SLEDAI-2K. If present, each of the four SLEDAI-R items receives a score of 4: 
proteinuria of > 0.5 gram/day, hematuria and pyuria (both > 5 cells/high power field), and 
cellular casts (4). Besides the items included in the SLEDAI-R, the renal domain of the 
BILAG Index (BILAG-R) contains the following items: accelerated hypertension, nephrotic 
syndrome; serum creatinine concentrations, creatinine clearance, and signs of active LN on 
kidney biopsy in the preceding 3-month period. Based on the degree of abnormalities of the 
BILAG-R items an alphabetical BILAG-R score (A – E) can be deduced. For this study the 
alphabetical scores were converted into numerical scores (A = 12; B = 8; C = 1; D and E = 
0) as previously suggested (4, 11). The scores of the BILAG-R range from 0 to 12 with 
higher scores signifying a more urgent need for therapeutic interventions. The SLICC-RAS 
considers various degrees of hematuria, pyuria and proteinuria in its summary score, all 
scored on Likert scales (5).
Clinical measures of kidney damage are the Systemic Lupus International Collaborating 
Clinics-Damage Index (SDI-R, score = 0 to maximum of 3) with scores given for the 
presence of at least 6 months of a 50% reduction in normal creatinine clearance, daily 
proteinuria exceeding 3.5 grams, and the need for renal replacement therapy (12). We also 
collected data on using the Chronic Kidney Disease (CKD) classification system, which is a 
generic measure of kidney function based on glomerular filtration rate (GFR) (13). CKD 
Stage 1 reflects GFR of at least 90 ml/min/1.73m2; Stage 2 is a GFR between 60 and 89 
ml/min/1.73m2; Stage 3 between 30 and 59 ml/min/1.73m2, Stage 4 between 15 and 29 
ml/min/1.73m2, and Stage 5 less than 15 ml/min/1.73m2.
Criterion standard – kidney biopsy findings
The International Society of Nephrology and the Renal Pathology Society (ISN/RPS) 
developed a framework for the classification of LN (14). Features from active inflammation 
is traditionally quantified using the NIH Activity Index (NIH-AI; score range: 0 – 24; 0 = no 
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active features) (7). The NIH-AI score is based on the proportion of the kidney biopsy 
showing histological features indicative of active inflammation with LN: endocapillary 
hypercellularity with/without leukocyte infiltration and substantial luminal reduction, 
karyorrhexis (fibrinoid necrosis), rupture of glomerular basement membrane, fibrocellular 
crescents, subendothelial deposits identifiable by light microscopy (wire loops), and 
intraluminal immune aggregates (hyaline thrombi) (7). Recently, the Tubulointerstitial 
Activity Index (TIAI; score range: 0– 21; 0 = no active features) has been developed to 
provide more detailed information about inflammatory changes in the kidney interstitium 
(8). The TIAI score considers tubular cell pyknosis, nuclear activation, necrosis, flattening, 
macrophages in the tubular lumens, epithelial cells in the tubular lumens, and interstitial 
inflammation (8, 15).
Permanent kidney damage as seen on kidney biopsy is commonly quantified using the NIH 
Chronicity Index (NIH-CI; score range: 0 –12; 0 = no chronicity) (7). The NIH-CI reflects 
features of damage in LN: glomerular sclerosis (segmental or global), fibrous adhesions or 
fibrous crescents, interstitial fibrosis, and tubular atrophy (7).
Interpretation of kidney biopsy specimens
All kidney biopsy slides were digitalized and scanned (ScanScope XT system by Aperio) for 
interpretation by one pediatric nephropathologist (DW), in order to minimize inter-observer 
variation (16). Biopsy slides included stains for hematoxylin and eosin, trichrome, and 
immunofluorescence with C3, C4, C5, C1q, IgG, IgM, and IgA. Electron microscopy 
pictures were collected and used as a means to facilitate the interpretation according to the 
ISN/RPS classification. The nephropathologist identified the ISN/RPS Class and summary 
scores of the NIH-AI, NIH-CI and TIAI for the biopsy specimens.
Statistical analysis
Descriptive statistics included means and standard deviations (SD) or standard errors (SE), 
medians and interquartile ranges, for numerical variables, and frequencies for categorical 
variables respectively. Spearman correlation coefficients (r) were used to assess 
relationships between the scores of clinical LN indices (SLEDAI-R, BILAG-R, SLICC-
RAS, SDI-R) and histological indices (NIH-AI, TIAI, NIH-CI, ISN/RPS class), Values of r 
can be interpreted as follows: unrelated: r < |0.2|; weakly related: |0.2| ≤ r < |0.4|; and 
moderately related: |0.4| ≤ r < |0.6|. Next, we compared clinical LN activity (SLEDAI-R, 
BILAG-R, SLICC-RAS) and LN damage measures (SDI-R, CKD stage) for their 
differences in means between high vs. low/moderate histological LN activity (defined as 
NIH AI > 10 vs. ≤ 10, or TIAI score > 5 vs. ≤ 5), the presence vs. absences of LN chronicity 
(defined as NIH CI ≥ 1 vs. 0), and ISN/RPS by classes using fixed effect models, after 
considering both unadjusted and adjusted methods; in the latter, differences in demographic 
variables between groups, such as age and race/ethnicity, were used as adjusting covariates. 
Multiple comparisons between two or more groups were adjusted using a Tukey’s method. 
In addition, we used non-parametric methods such as Wilcoxon rank sum and Kruskal 
Wallis tests were used to confirm results from the parametric fixed effect models (data not 
shown). Since findings from different methods were all consistent, only the results from 
unadjusted fixed models are presented.
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We also determined for the LN damage status sensitivity, specificity and the positive (LR+) 
and the negative likelihood ratios (LR−) reflecting LN damage status. LR+ is defined as 
sensitivity/(1-specificity) and LR− is defined as (1-sensitivity)/specificity. LR +values can 
be interpreted as: > 10: large, often conclusive increase in the likelihood of “ruling in” the 
presence of LN chronicity (NIH-CI > 0); 5 – 9.9: moderate increase; and 2 – 4.9: small 
increase, respectively. In other words, a LR+ of 2 increases the probability for a LN 
chronicity by 15%, a LR+ of 5 increases it by 30%, and a LR+ of 10 increases it by 45% 
(17). LR− can be interpreted accordingly for “ruling-out” LN chronicity. All statistical 
analyses were performed using a SAS 9.4 software (SAS, Cary, NC) package. P-values < 
0.05 were considered statistically significant.
RESULTS
Patients
At the time of the study, the mean (SD) age of the patients was 15.5 (2.7) years. A total of 
65 patients (77%) were female; 34 (41%) were Caucasian and 30 (36%) were African 
American (Table 1). The mean extra-renal disease activity as measured by SLEDAI was 
moderate, with arthritis and mucocutaneous involvement constituting the most common 
extra-renal manifestations (Supplementary table 1). Proliferative LN (class III and IV) as 
present in 60% of the patients, while 28% had class V. None of the patients had Class VI but 
15% of the patients had CKD stage 3 or higher.
Association between histological and clinical measures of LN-activity
None of the patients had a SLEDAI-R, SLICC-RAS or BILAG-R score of 0 at the time of 
biopsy. Scores of the SLEDAI-R were moderately and those of the SLICC-RAS and 
BILAG-R, weakly correlated with the NIH-AI scores (Table 2). TIAI scores were only 
correlated with the SLEDAI-R scores but not with those of the BILAG-R or SLICC-RAS.
As shown in Figure 1, the mean scores of the SLEDAI-R differed with LN activity status 
defined by the NIH-AI and TIAI scores, respectively. This was not the case for the BILAG-
R scores that did not differ with LN activity status (NIH-AI, TIAI).
Associations between treatment with angiotensin-coverting enzyme inhibitors (ACEI) or 
angiotensin receptor blockers (ARB) to NIH AI and TIAI were assessed yet the results were 
not statistically significant. In particular, for those (N = 27) with ACEI/ARB, 7/27 or 26% 
have NIH AI score > 10; and for N = 44 who don’t have ACE/ARB, 17/44 or 38.6% have 
NIH AI score > 10 (p-value = 0.27). Similar results were obtained when comparing TIAI >5 
(p-value = 0.95).
Relationship between histologically proven LN chronicity and clinical measures of LN 
damage
SDI-R scores of 1 or higher were more common in patients with vs. without biopsy-proven 
kidney chronicity (p-value = 0.08). Although the sensitivity of SDI-R to capture LN 
chronicity (NIH-CI > 0) was only 23%, it was highly specific (91.7%), resulting in a LR+ of 
2.8 and a LR− of 0.83. In addition, patients with LN chronicity were more likely to have 
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more severe CKD (stages 3 and 4) than patients with NIH-CI scores of 0 (Table 3). Notably, 
most children maintained normal GFR even in the presence of LN chronicity.
CKD stages 3 or 4 were only present in patients with NIH-CI scores > 0. Therefore, the 
presence of CKD stage 3 or worse was 100% sensitive and 73.5% specific for the presence 
of LN chronicity (LR+: 3.8; LR−: 0). A less stringent cut-off at CKD stage 2 or worse had a 
sensitivity and specificity of 35% and 70% for the presence of LN chronicity (LR+: 1.5; LR
−: 0.94).
Clinical measures of LN activity are associated with histological measures of kidney 
damage
Although designed to estimate LN activity, the mean scores of the SLEDAI-R and SLICC-
RAS but not BILAG-R, were significantly higher in patients with NIH-CI scores > 0 (Table 
4). The mean scores of the SLICC-RAS also significantly differed by LN damage status as 
measured by the SDI-R. The mean scores of the LN clinical indices were generally higher in 
patients with CKD stage 3–5 than stage 1–2. Adjusting for ACEI or ARB usage did not 
significantly change these findings.
Relationship of ISN/RPS class and LN clinical indices
At the time of kidney biopsy, the mean SLEDAI-R scores with class IV LN were 
significantly higher than with other classes of LN. In contrast, neither the SLICC-RAS nor 
the BILAG-R scores differed significantly among the various classes of LN. Notably, the 
SLEDAI-R and BILAG-R scores for class I/II LN were almost identical to those of class III 
LN (Table 5). There was a trend towards more clinical LN damage (SDI-R scores > 0) with 
higher classes of LN (p-value = 0.167) and also a trend of higher CKD stages with higher 
classes of LN (p-value = 0.072).
DISCUSSION
Kidney biopsies provide information about the degree of inflammation and accrued damage 
with LN. It is impractical to use repeat kidney biopsies for monitoring LN, especially in the 
setting of apparent clinical remission and stable kidney function. Hence, surrogate measures 
of LN activity and LN damage have been proposed and used in clinical and research settings 
for many years. We present herein the first formal validation of such indices in children with 
LN. The results suggest that the SLEDAI-R and SLICC-RAS but not the BILAG-R differed 
with LN-activity status defined by NIH-AI scores, while only the SLEDAI-R scores differed 
between LN-activity status based on TIAI scores. Despite being specific, the SDI-R lacks 
sufficient sensitivity to identify true kidney damage.
While our goal was not to suggest that LN clinical indices can replace kidney biopsies, it is 
important that we evaluate and validate these clinical indices that are commonly used in 
clinical practice and research. LN clinical indices are comprised of individual laboratory 
tests, including complement levels, anti-double-stranded DNA, antibodies and proteinuria 
that have been shown individually to reflect active LN activity as seen on kidney biopsy.
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The SLEDAI-R was the only clinical index that differentiated between the degree of both 
glomerular and tubulointerstitial inflammation as measured by the NIH-AI and TIAI, 
respectively. Indeed, the SLEDAI-R was superior to the SLICC-RAS and BILAG-R in 
capturing LN activity. Reasons observed in our data were that blood-pressure measurement 
and other items considered in the BILAG-R only poorly correlate with LN activity in 
children. The SLICC-RAS has similar components as the SLEDAI-R, which may explain 
why the SLICC-RAS performed somewhat better than the BILAG-R in reflecting 
histological proven LN activity. When considering ease of use, and its known 
reproducibility, the SLEDAI-R is probably the most appropriate clinical index for measuring 
LN activity in children with LN.
Among patients with histological damage, we found that the presence of any renal damage 
captured by the SDI was highly specific but insensitive to the presence of histologically 
confirmed LN chronicity. Nonetheless, a positive SDI-R score increases the likelihood for 
the presence of LN chronicity by about 20% and therefore helps to a limited degree to “rule-
in” LN-chronicity. Conversely, a SDI-R score of ‘0’ provides little information to help 
“ruling-out” the presence of histologically-confirmed kidney damage.
Chronic proteinuria is considered in the score of the SDI-R and proteinuria is also a key 
feature of active LN. Thus it might be expected that the scores of the SLEDAI-R, BILAG-R 
and SLICC-RAS would be higher in patients with LN chronicity. As done for this study, 
there is the proviso in the completion of all of these indices that the proteinuria should be 
considered to be part of active LN. Supported by our findings, it may put patients with 
proteinuria at risk of unnecessary exposure to immunosuppressives for erroneously 
presumed active LN and vice versa.
This study is not without its limitations. Despite being the criterion standard for staging and 
classifying LN, needle kidney biopsies of children have often only provide few glomeruli 
and little interstitial tissue. This may limit the accuracy of histological interpretation of 
kidney biopsies (18, 19). However, all histological findings reported in this study were 
interpreted by a one expert nephropathologist who omitted scoring of histological indices 
when deemed appropriate due to inferior biopsy quality. We since then asked three other 
nephropathologists to reinterpret the biopsies and found other raters to provide very similar 
scoring (unpublished observations). Further, due to the limited number of repeat biopsies 
(only two patients), we were only able to analyze the data in a cross-sectional fashion. It will 
be ideal to evaluate the responsiveness of the LN clinical indices to histological changes in 
repeat kidney biopsies in the future.
In summary, this study stresses the need for improved non-invasive measures of LN activity 
and LN damage. Although uncommonly performed in pediatrics, serial LN biopsies may 
prove beneficial to verify response to anti-inflammatory LN therapy. This notion is in line 
with recent studies in adults that demonstrated ongoing renal inflammation despite 
normalized LN clinical indices (20). Furthermore, the results of our study emphasize the 
need for routine access to testing of novel urine biomarkers in LN. There is a large body of 
evidence supporting the accuracy and even predictive properties of novel urine biomarkers 
for LN (21). However, none of the proposed LN novel biomarker panels are commercially 
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available at this time or approved for use as companion diagnostics or biomarker in clinical 
trial of LN. In the meantime, we recommend using the SLEDAI-R to measure LN activity in 
children with LN.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE AND INNOVATION
• We newly provide evidence that the renal domain score of the SLEDAI 
(SLEDAI-R) is more reflective of histologically confirmed LN activity than the 
SLICC-RAS and the BILAG-R in children with LN.
• The SDI-R scores of 1 or higher are specific for the presence of LN damage but 
they lack sensitivity.
• Most children with LN have normal kidney function despite the presence of 
active LN, even when renal damage is present.
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Figure 1. 
Differences in the scores of clinical indices of LN-activity with high vs. moderate/low LN-
activity by kidney biopsy
†Values are means and SE; p-values based on test-tests comparing means of Lupus Nephritis 
Clinical Indices for low versus high NIH AI Score and TIAI Score, with cut-offs defined in 
the table
† LN-activity NIH-AI high vs. moderate/low is defined based on NIH-AI scores > 10 vs. ≤ 10
‡ LN-activity TIAI high vs. moderate/low is defined based on TIAI scores > 5 vs. ≤ 5
* Not significant
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Table 1
Baseline characteristics of the patients
Characteristics Number (%)(N=83) Mean (Standard deviation)
Females 65 (77)
Race
 Caucasian 34 (41.0)
 African-American 30 (36.1)
 Asian with Pacific Islander 7 (8.4)
 American Indian 1 (1.2)
 Mixed 11 (13.3)
Ethnicity
 Hispanic 10 (12.1)
 Non-Hispanic 73 (87.9)
Age (in years) 15.53 (2.71)
Disease duration (in years) 1.52 (0.96)
Extra-renal SLEDAI* 8.13 (6.61)
ISN/RPS classŦ
 I 1 (1.2)
 II 9 (10.8)
 III 15 (18.1)
 IV 35 (42.2)
 V 23 (27.7)
 VI 0
Biopsy interval (in days)¶ 83 10 (3)
NIH-AI† 71 7.82 (6.8)
TIAI¶¶ 55 4 (0, 11)
NIH-CI# 70 1.77 (1.75)
Pyuria (> 5 white blood cells/high power field) 39 (46.9)
Hematuria (> 5 red blood cells/high power field) 50 (60.2)
Urine casts 14 (16.8)
Urine protein/creatinine ratio mg/dL) 3.4 (3.2)
SDI-R** 83 0.36 (0.61)
CKD StageŦŦ
 1 56 (67.5)
 2 16 (19.3)
 3 6 (7.2)
 4 4 (4.8)
 5 1 (1.2)
Medications
 Prednisone dose (mg/day) 34 (19.2)
 Hydroxychloroquine 72 (87)
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Characteristics Number (%)(N=83) Mean (Standard deviation)
 Mycophenolate mofetil 31 (37.3)
 Azathiopine 3 (3.6)
 Cyclophosphamide 21 (25.3)
 Methylprednisolone pulse 16 (19.2)
  Angiotensin converting enzyme inhibitor 27 (32.5)
  Angiotensin II receptor blocker 6 (7.2)
*
Extra-renal SLEDAI: Sum of the Systemic Lupus Erythematosus Disease Activity Index except the renal domain score
Ŧ
ISN/RPS: International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification for lupus nephritis
¶
Biopsy interval: interval in days between time of kidney biopsy and measurement of lupus nephritis clinical indices
†NIH-AI: National Institutes of Health-Activity Index (score = 0 to maximum of 24). Based on proportion of the kidney biopsy with: endocapillary 
hypercellularity with/without leukocyte infiltration and substantial luminal reduction, karyorrhexis, rupture of glomerular basement membrane, 
fibrocellular crescents, wire loops, and hyaline thrombi
¶¶
TIAI: Tubulointerstitial Activity Index (score = 0 to maximum of 21). Based on: tubular cell pyknosis, nuclear activation, necrosis, flattening, 
macrophages and epithelial cells in the tubular lumens, and interstitial inflammation
#NIH-CI: National Institutes of Health-Chronicity Index (score = 0 to maximum of 12). Based on: glomerular sclerosis, fibrous adhesions or 
fibrous crescents, interstitial fibrosis, and tubular atrophy
**SDI-R: Systemic Lupus International Collaborating Clinics-Damage Index (score = 0 to maximum of 5). Based on glomerular filtration rate 
(GFR) < 50%, presence of end stage renal disease and proteinuria > 3.5 gram/day
ŦŦCKD: Chronic Kidney Disease Stage 1: normal glomerular filtration rate (GFR); Stage 2: GFR 60–89 ml/min/1.73m2; Stage 3: GFR 30–59 
ml/min/1.73m2; Stage 4: GFR 15–29 ml/min/1.73m2; Stage 5: GFR <15 ml/min/1.73m2
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Table 4
Mean Scores of Lupus Nephritis Clinical Indices in Relation to Kidney Damage *
Clinical Measures of Activity
SLEDAI-R BILAG-R SLICC-RAS
Histological Measure of Damage
NIH CI Score
0 (N=34) 7.83 ± 0.83 10.89 ± 0.50 4.26 ± 0.92
> 0 (N=36) 10.82 ± 0.85 10.82 ± 0.51 7.69 ± 0.95
P-value 0.014 NS 0.012
SDI-R¶
0 (N=68) 8.32 ± 0.62 10.66 ± 0.37 5.18 ± 0.64
> 0 (N=14) 11.14 ± 1.36 10.86 ± 0.81 11.45 ± 1.52
P-valueŦ 0.062 0.823 0.000
Chronic Kidney Disease
Stage 1 (N=54) 8.00 ± 0.66† 10.36 ± 0.42 5.64 ± 0.78
Stage 2 (N=16) 8.63 ± 1.22† 10.81 ± 0.76 4.80 ± 1.38
Stage 3 (N=6) 12.00 ± 1.99 12.00 ± 1.24 9.83 ± 2.18
Stage 4 or 5 (N=5) 15.20 ± 2.18 12.00 ± 1.36 10.20 ± 2.39
*Values are means (95%CI)
Ŧ
P-values based on t-test comparing means of Lupus Nephritis Clinical Indices for low versus high NIH CI Score, with cut-offs defined in the table
¶SDI-R: Systemic Lupus International Collaborating Clinics-Damage Index (score = 0 to maximum of 5). Based on glomerular filtration rate 
(GFR) < 50%, presence of end stage renal disease and proteinuria > 3.5 gram/day
ŦŦCKD Stage 1: normal GFR; Stage 2: GFR 60–89 ml/min/1.73m2; Stage 3: GFR 30–59 ml/min/1.73m2; Stage 4: GFR 15–29 ml/min/1.73m2; 
Stage 5: GFR <15 ml/min/1.73m2
†
Means are statistically different from that of State 4+5, in post hoc tests after adjusting for multiple comparison using a Bonferroni’s method.
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